Ascendis Pharma A/S (FRA:A71)

Ascendis Pharma Statistics

Total Valuation

Ascendis Pharma has a market cap or net worth of EUR 11.08 billion. The enterprise value is 11.36 billion.

Market Cap	11.08B
Enterprise Value	11.36B

Important Dates

The next estimated earnings date is Wednesday, February 11, 2026.

Earnings Date	Feb 11, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+5.56%
Shares Change (QoQ)	-4.94%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	60.63M

Valuation Ratios

PE Ratio	n/a
Forward PE	77.65
PS Ratio	17.14
PB Ratio	-63.66
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-48.76
EV / Sales	17.41
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-101.28

Financial Position

The company has a current ratio of 1.03

Current Ratio	1.03
Quick Ratio	0.70
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-7.25
Interest Coverage	-0.99

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-7.69%
Return on Invested Capital (ROIC)	-12.99%
Return on Capital Employed (ROCE)	-82.18%
Revenue Per Employee	635,740
Profits Per Employee	-229,047
Employee Count	1,017
Asset Turnover	0.58
Inventory Turnover	0.30

Taxes

In the past 12 months, Ascendis Pharma has paid 9.61 million in taxes.

Income Tax	9.61M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +41.27% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+41.27%
50-Day Moving Average	173.98
200-Day Moving Average	155.02
Relative Strength Index (RSI)	51.74
Average Volume (20 Days)	8

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	6.33

Income Statement

In the last 12 months, Ascendis Pharma had revenue of EUR 646.55 million and -232.94 million in losses. Loss per share was -3.87.

Revenue	646.55M
Gross Profit	561.21M
Operating Income	-138.28M
Pretax Income	-223.33M
Net Income	-232.94M
EBITDA	-133.71M
EBIT	-138.28M
Loss Per Share	-3.87

Balance Sheet

The company has 539.09 million in cash and 813.65 million in debt, giving a net cash position of -274.56 million.

Cash & Cash Equivalents	539.09M
Total Debt	813.65M
Net Cash	-274.56M
Net Cash Per Share	n/a
Equity (Book Value)	-174.08M
Book Value Per Share	-2.85
Working Capital	31.30M

Cash Flow

In the last 12 months, operating cash flow was -106.68 million and capital expenditures -5.48 million, giving a free cash flow of -112.15 million.

Operating Cash Flow	-106.68M
Capital Expenditures	-5.48M
Free Cash Flow	-112.15M
FCF Per Share	n/a

Margins

Gross margin is 86.80%, with operating and profit margins of -21.39% and -36.03%.

Gross Margin	86.80%
Operating Margin	-21.39%
Pretax Margin	-34.54%
Profit Margin	-36.03%
EBITDA Margin	-20.68%
EBIT Margin	-21.39%
FCF Margin	n/a

Dividends & Yields

Ascendis Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-5.56%
Shareholder Yield	-5.56%
Earnings Yield	-2.10%
FCF Yield	-1.01%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Ascendis Pharma has an Altman Z-Score of 0.74 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.74
Piotroski F-Score	4